LRRK2 phosphorylates novel tau epitopes and promotes tauopathy

Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies

(2013) Paul Davies et al.   BIOCHEMICAL JOURNAL

Tau pathology and neurodegeneration

(2013) Maria Grazia Spillantini et al.   LANCET NEUROLOGY

Cellular effects of LRRK2 mutations

(2012) Mark R. Cookson   BIOCHEMICAL SOCIETY TRANSACTIONS

(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD

(2012) C-Y Chen et al.   CELL DEATH AND DIFFERENTIATION

Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases

(2012) Giovanni Coppola et al.   HUMAN MOLECULAR GENETICS

The neuropathology of genetic Parkinson's disease

(2012) Markos Poulopoulos et al.   MOVEMENT DISORDERS

The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features

(2012) Eleanna Kara et al.   NEUROBIOLOGY OF AGING

LRRK2 I2020T mutation is associated with tau pathology

(2012) Sachiko Ujiie et al.   PARKINSONISM & RELATED DISORDERS

LRRK2 Phosphorylates Tubulin-Associated Tau but Not the Free Molecule: LRRK2-Mediated Regulation of the Tau-Tubulin Association and Neurite Outgrowth

(2012) Fumitaka Kawakami et al.   PLoS One

Unclassifiable tauopathy associated with an A152T variation in MAPT exon 7

(2011) G.G. Kovacs et al.   CLINICAL NEUROPATHOLOGY

LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: Impairment of the kinase activity by Parkinson's disease-associated mutations

(2011) Etsuro Ohta et al.   FEBS LETTERS

Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD

(2011) Markos Poulopoulos et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study

(2011) Owen A Ross et al.   LANCET NEUROLOGY

Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts

(2011) Kurt A. Jellinger   MOVEMENT DISORDERS

The Many Faces of Tau

(2011) Meaghan Morris et al.   NEURON

LRRK2 and Parkinson Disease

(2010) Justus C. Dächsel et al.   ARCHIVES OF NEUROLOGY

Spectroscopic Studies of GSK3β Phosphorylation of the Neuronal Tau Protein and Its Interaction with the N-terminal Domain of Apolipoprotein E

(2010) Arnaud Leroy et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition

(2010) Jason P. Covy et al.   JOURNAL OF NEUROCHEMISTRY

LRRK2 G2019S Mutation Induces Dendrite Degeneration through Mislocalization and Phosphorylation of Tau by Recruiting Autoactivated GSK3 

(2010) C.-H. Lin et al.   JOURNAL OF NEUROSCIENCE

Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson's Disease Mutation G2019S

(2010) X. Li et al.   JOURNAL OF NEUROSCIENCE

Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice

(2010) H.L. Melrose et al.   NEUROBIOLOGY OF DISEASE

Signal Transduction Protein Array Analysis Links LRRK2 to Ste20 Kinases and PKC Zeta That Modulate Neuronal Plasticity

(2010) Susanne Zach et al.   PLoS One

Leucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three Questions

(2009) Elisa Greggio et al.   ASN Neuro

Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications

(2009) Hong Qing et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease

(2009) R. Jeremy Nichols et al.   BIOCHEMICAL JOURNAL

The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7,in vitro

(2009) Christian Johannes Gloeckner et al.   JOURNAL OF NEUROCHEMISTRY

Leucine-Rich Repeat Kinase 2 Expression Leads to Aggresome Formation That Is Not Associated With α-Synuclein Inclusions

(2009) Elisa A. Waxman et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Mutant LRRK2 R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease

(2009) Yanping Li et al.   NATURE NEUROSCIENCE

Clinical features of LRRK2 parkinsonism

(2009) Kristoffer Haugarvoll et al.   PARKINSONISM & RELATED DISORDERS

Tau phosphorylation: the therapeutic challenge for neurodegenerative disease

(2009) Diane P. Hanger et al.   TRENDS IN MOLECULAR MEDICINE

Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease

(2008) Owen A. Ross et al.   ANNALS OF NEUROLOGY

Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2

(2008) Jason P. Covy et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease

(2008) Saskia Biskup et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Investigation of leucine-rich repeat kinase 2

(2008) Vasanti S. Anand et al.   FEBS Journal

Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells

(2008) Edward D. Plowey et al.   JOURNAL OF NEUROCHEMISTRY

Clinical and pathological characteristics of patients with Leucine-rich repeat kinase-2 mutations

(2008) Jason P. Covy et al.   MOVEMENT DISORDERS

Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway

(2008) Anthony K.F. Liou et al.   NEUROBIOLOGY OF DISEASE